[go: up one dir, main page]

PL3740504T3 - Skojarzona terapia CD70 - Google Patents

Skojarzona terapia CD70

Info

Publication number
PL3740504T3
PL3740504T3 PL19702014.2T PL19702014T PL3740504T3 PL 3740504 T3 PL3740504 T3 PL 3740504T3 PL 19702014 T PL19702014 T PL 19702014T PL 3740504 T3 PL3740504 T3 PL 3740504T3
Authority
PL
Poland
Prior art keywords
combination therapy
therapy
combination
Prior art date
Application number
PL19702014.2T
Other languages
English (en)
Inventor
Luc Van Rompaey
Tim DELAHAYE
Mahan Moshir
Piotr ZABROCKI
Original Assignee
Argenx Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenx Bvba filed Critical Argenx Bvba
Publication of PL3740504T3 publication Critical patent/PL3740504T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL19702014.2T 2018-01-16 2019-01-16 Skojarzona terapia CD70 PL3740504T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1800649.4A GB201800649D0 (en) 2018-01-16 2018-01-16 CD70 Combination Therapy
PCT/EP2019/051058 WO2019141732A1 (en) 2018-01-16 2019-01-16 Cd70 combination therapy

Publications (1)

Publication Number Publication Date
PL3740504T3 true PL3740504T3 (pl) 2024-01-29

Family

ID=61256176

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19702014.2T PL3740504T3 (pl) 2018-01-16 2019-01-16 Skojarzona terapia CD70

Country Status (22)

Country Link
US (2) US11530271B2 (pl)
EP (2) EP3740504B9 (pl)
JP (2) JP7511479B2 (pl)
KR (1) KR102790232B1 (pl)
CN (1) CN111836830B (pl)
AU (1) AU2019209503B2 (pl)
BR (1) BR112020014321A2 (pl)
CA (1) CA3086448A1 (pl)
DK (1) DK3740504T5 (pl)
EA (1) EA202091714A1 (pl)
ES (1) ES2956258T3 (pl)
FI (1) FI3740504T3 (pl)
GB (1) GB201800649D0 (pl)
HU (1) HUE063783T2 (pl)
IL (1) IL276103A (pl)
LT (1) LT3740504T (pl)
MX (1) MX2020007606A (pl)
PL (1) PL3740504T3 (pl)
PT (1) PT3740504T (pl)
SG (1) SG11202006007YA (pl)
WO (1) WO2019141732A1 (pl)
ZA (1) ZA202003986B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2828753C (en) 2011-03-16 2022-07-26 arGEN-X BV Antibodies to cd70
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
CN118994394A (zh) 2017-06-12 2024-11-22 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
BR112021005585A2 (pt) 2018-09-27 2021-06-29 Celgene Corporation proteínas de ligação a sirpa e métodos de uso das mesmas
TWI848030B (zh) * 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
TW202124443A (zh) * 2019-09-16 2021-07-01 瑞士商諾華公司 高親和力的、配位基阻斷性、人源化的抗T細胞免疫球蛋白結構域和黏蛋白結構域3(TIM-3)IgG4抗體用於治療骨髓纖維化之用途
EP4090335A1 (en) * 2020-01-17 2022-11-23 Novartis AG Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
WO2021226289A2 (en) * 2020-05-05 2021-11-11 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
EP4232052A4 (en) * 2020-10-22 2025-08-20 Actinium Pharmaceuticals Inc COMBINATION OF RADIOMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER
CN114765061B (zh) * 2021-01-15 2024-12-27 深圳哲源生物科技有限责任公司 Pd-1/pd-l1抑制剂的不良预后的数据处理系统及方法
CN113150140B (zh) * 2021-01-25 2022-11-04 山西农业大学 一种sox6二价纳米抗体及其应用
IL309405A (en) * 2021-06-29 2024-02-01 Seagen Inc Methods for treating cancer with a combination of non-fucosylated anti-CD70 antibody and CD47 antagonist
WO2024126833A1 (en) * 2022-12-16 2024-06-20 Ichnos Sciences SA Cd47-il1rap bispecific antibodies

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US6500633B1 (en) 2000-04-26 2002-12-31 Atairgin Technologies, Inc. Method of detecting carcinomas
US20030148321A1 (en) 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
WO2003039443A2 (en) 2001-11-05 2003-05-15 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
WO2003046581A2 (en) 2001-11-27 2003-06-05 Oxford Glycosciences (Uk) Ltd Methods for diagnosis and treatment of epithelial-derived cancers,such as colorectal cancers and kidney cancers
US7261892B2 (en) 2001-11-27 2007-08-28 Celltech R&D Limited Methods for diagnosis and treatment of epithelial-derived cancers
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8039218B2 (en) 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
WO2004073656A2 (en) 2003-02-20 2004-09-02 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
MXPA05010134A (es) 2003-03-24 2005-11-16 Zymogenetics Inc Anticuerpos anti-il-20, metodos y moleculas de enlace que se usan en la inflamacion.
ES2526343T3 (es) 2004-06-03 2015-01-09 Novimmune Sa Anticuerpos anti-CD3 y métodos de uso de los mismos
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
EP1799262A4 (en) 2004-10-15 2009-10-21 Seattle Genetics Inc ANTI-CD70 ANTIBODIES AND ITS USE FOR THE TREATMENT AND PREVENTION OF CANCER DISORDERS AND IMMUNE DISORDERS
US7537761B2 (en) 2004-10-22 2009-05-26 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
EP2511299A1 (en) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
WO2006113747A2 (en) 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
WO2007011856A2 (en) 2005-07-15 2007-01-25 The Trustees Of Columbia University In The City Of New York Compositions and methods for differential diagnosis of chronic lymphocytic leukemia
CA2623236A1 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
KR100807069B1 (ko) 2007-09-21 2008-02-25 고려대학교 산학협력단 암 치료용 의약 조성물
KR20100089869A (ko) 2007-11-05 2010-08-12 노파르티스 아게 Ｗｎｔ 활성화의 측정 및 ｗｎｔ-관련 암의 치료를 위한 방법 및 조성물
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010014948A1 (en) 2008-08-01 2010-02-04 The University Of Utah Research Foundation Methods of treatment using wnt inhibitors
US20110190157A1 (en) 2008-08-15 2011-08-04 The Regents Of The University Of California Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia
MX2011003183A (es) 2008-09-26 2011-04-21 Oncomed Pharm Inc Agentes que se unen a receptor encrespado y usos de los mismos.
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
WO2011019651A1 (en) 2009-08-10 2011-02-17 Epitherix, Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
US20120178111A1 (en) 2009-09-23 2012-07-12 Diamandis Eleftherios P Methods and compositions for the detection of lung cancers
PH12012500924A1 (en) 2009-11-19 2012-11-26 Merck Serono Sa Humanized antibodies against human il-22ra
EP2520589B1 (en) 2009-12-29 2018-11-07 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
HUE040213T2 (hu) 2010-06-11 2019-02-28 Kyowa Hakko Kirin Co Ltd Anti-TIM antitest
EP3508498A1 (en) 2011-01-19 2019-07-10 Cantargia AB Novel agents and uses thereof
CA2828753C (en) 2011-03-16 2022-07-26 arGEN-X BV Antibodies to cd70
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
ES2806146T3 (es) 2011-09-22 2021-02-16 Amgen Inc Proteínas de unión al antígeno CD27L
WO2013093508A2 (en) 2011-12-22 2013-06-27 Oslo University Hospital Hf Wnt pathway inhibitors
PE20142242A1 (es) 2012-03-15 2015-01-08 Janssen Biotech Inc Anticuerpos humanos anti-cd27, metodos, y usos
US20150086521A1 (en) 2012-03-21 2015-03-26 Erytech Pharma Medicament for the Treatment of Acute Myeloid Leukemia (AML)
US9801851B2 (en) 2012-05-23 2017-10-31 St. Jude Children's Research Hospital Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias
EP2861590B1 (en) 2012-06-15 2017-10-25 Curegenix Inc. Compound as wnt signaling inhibitor, composition, and use thereof
JP6391574B2 (ja) 2012-08-31 2018-09-26 アルゲン−エックス ビーブイビーエー 種間標的内交差反応性を有する抗体分子を産生する方法
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
US20150315279A1 (en) 2012-12-21 2015-11-05 Cellerant Therapeutics, Inc. Antibodies that bind membrane-bound il1rap
SI2956173T1 (sl) 2013-02-14 2017-06-30 Bristol-Myers Squibb Company Spojine tubulizina, postopki pridobivanja in uporaba
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
JP6606505B2 (ja) * 2014-03-11 2019-11-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
TWI717375B (zh) * 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
WO2017044752A1 (en) * 2015-09-10 2017-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
SI3370768T1 (sl) 2015-11-03 2022-04-29 Janssen Biotech, Inc. Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
US11027021B2 (en) 2016-03-15 2021-06-08 Seagen Inc. Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
GB2567613A (en) 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
WO2020181219A1 (en) 2019-03-06 2020-09-10 The Regents Of The University Of Colorado, A Body Corporate Methods of detecting and treating venetoclax-resistant acute myeloid leukemia
IL300996A (en) 2020-08-29 2023-04-01 argenx BV Treatment method for patients with reduced sensitivity to BCL-2 inhibitor
AU2021358768A1 (en) 2020-10-06 2023-05-18 The Regents Of The University Of Colorado, A Body Corporate Subject-specific treatments for venetoclax-resistant acute myeloid leukemia

Also Published As

Publication number Publication date
DK3740504T5 (da) 2024-07-15
EP3740504B1 (en) 2023-07-19
ES2956258T3 (es) 2023-12-18
AU2019209503A1 (en) 2020-07-09
ZA202003986B (en) 2025-04-30
EP4275702A2 (en) 2023-11-15
SG11202006007YA (en) 2020-08-28
DK3740504T3 (da) 2023-10-23
WO2019141732A9 (en) 2020-05-22
CA3086448A1 (en) 2019-07-25
AU2019209503B2 (en) 2025-08-28
KR20200110658A (ko) 2020-09-24
US11530271B2 (en) 2022-12-20
EP3740504B9 (en) 2023-11-22
BR112020014321A2 (pt) 2020-12-08
MX2020007606A (es) 2020-09-03
JP2024037765A (ja) 2024-03-19
EA202091714A1 (ru) 2020-10-15
FI3740504T3 (fi) 2023-10-11
EP4275702A3 (en) 2024-02-28
CN111836830B (zh) 2024-08-23
KR102790232B1 (ko) 2025-04-03
LT3740504T (lt) 2023-09-11
US20240002523A1 (en) 2024-01-04
JP7511479B2 (ja) 2024-07-05
WO2019141732A1 (en) 2019-07-25
EP3740504A1 (en) 2020-11-25
US12180293B2 (en) 2024-12-31
GB201800649D0 (en) 2018-02-28
PT3740504T (pt) 2023-10-04
IL276103A (en) 2020-08-31
US20190241668A1 (en) 2019-08-08
JP2021510736A (ja) 2021-04-30
HUE063783T2 (hu) 2024-01-28
CN111836830A (zh) 2020-10-27

Similar Documents

Publication Publication Date Title
IL276103A (en) Combined treatment with 70cd
IL277336A (en) combined treatment
GB201804255D0 (en) Macrophage-based therapy
GB201819853D0 (en) Therapy
IL280729A (en) Combined treatment
IL279908A (en) Combined treatment
SG11202101518QA (en) Combination therapy
ZA202200731B (en) Combination therapy
IL288237A (en) Combined treatment
GB201914006D0 (en) Combination Therapy
GB201910473D0 (en) Combination therapy
GB201906864D0 (en) Combination therapy
GB201817385D0 (en) Therapy
GB201818579D0 (en) New therapy
GB201814036D0 (en) New therapy
GB201820582D0 (en) CD70 combination therapy
GB201917701D0 (en) CD70 Combination therapy
GB201911007D0 (en) CD70 combination therapy
GB201919301D0 (en) Combination therapy
GB201917254D0 (en) Combination therapy
GB201908225D0 (en) Combination therapy
GB201908227D0 (en) Combination therapy
GB201908233D0 (en) Combination therapy
GB201908232D0 (en) Combination Therapy
GB201908231D0 (en) Combination therapy